Codexis Announces Sale of Fabry and Pompe Disease Gene Therapy Programs to Crosswalk Therapeutics

Monday, 1 July 2024, 21:28

Codexis (CDXS) has reached a sales agreement with Crosswalk Therapeutics for its gene therapy programs targeting Fabry and Pompe diseases. This strategic move signifies a shift in Codexis' focus towards optimizing resources and fostering collaborations. The sale of these assets will provide Codexis with additional financial flexibility and enable the company to advance its core operations. Overall, the transaction with Crosswalk Therapeutics marks a significant development in Codexis' strategic portfolio management.

Seeking Alpha — Codexis Announces Sale of Fabry and Pompe Disease Gene Therapy Programs to Crosswalk Therapeutics

Codexis Sells Gene Therapy Assets to Crosswalk Therapeutics

Codexis (CDXS) has reached a sales agreement with Crosswalk Therapeutics for its gene therapy programs targeting Fabry and Pompe diseases.

This strategic move signifies a shift in Codexis' focus towards optimizing resources and fostering collaborations.

The sale of these assets will provide Codexis with additional financial flexibility.
The transaction enables Codexis to advance its core operations.
Overall, the sale to Crosswalk Therapeutics marks a significant development in Codexis' strategic portfolio management.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.